Company Overview

Update
Founded:
2008
Founders:
Jeff Wolf
Headquarters:
Chapel Hill, NC
IPO:
Went Public on Jul 24, 2013
Stock:
HTBX
Categories:
Health Care, Biotechnology
Description:
Heat Biologics, a clinical-stage company, offers ImPACT, an adjuvant technology to identify oncology and infectious disease indications.

Detailed Description

Update

Heat Biologics is a clinical-stage company focused on developing its proprietary “ImPACT” (Immune Pan-Antigen Cytotoxic Therapy) adjuvant technology for use in a number of oncology and infectious disease indications. Heat’s ImPACT therapy is a first-in-class fully human adjuvant system that functions as both an immune stimulator and an antigen-delivery system. ImPACT is rapidly applied to a selected off-the-shelf cancer cell line to effectively transform living tumor into powerful machines that “pump out” their full antigenic fingerprint to robustly stimulate the immune system against the targeted disease. ImPACT is applicable to a wide range of cancers as well as infectious diseases including HIV, HCV and malaria. Heat is currently in Phase II clinical trials with its first drug to treat Non Small Cell Lung Cancer (NSCLC) and plans to initiate clinical trials against additional cancers in 2012.

Current Team (8)

Update

Funding Rounds (3) - $8.1M

Update

Board Members and Advisors (10)

Update

Investors (1)

Update

Offices/Locations (1)

Update
  • Headquarters

    100 Europa Drive

    Suite 420

    Chapel Hill, NC 27517

    USA

Images (1)

Update
  • 5b81a1b7ba372f468e49097e9a21cd38